Cargando…
Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial
BACKGROUND: Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. OBJECTIVE: The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758845/ https://www.ncbi.nlm.nih.gov/pubmed/29441116 http://dx.doi.org/10.1155/2017/8780325 |
_version_ | 1783291076263542784 |
---|---|
author | Cheon, Chunhoo Yoo, Jeong-Eun Yoo, Hwa-Seung Cho, Chong-Kwan Kang, Sohyeon Kim, Mia Jang, Bo-Hyoung Shin, Yong-Cheol Ko, Seong-Gyu |
author_facet | Cheon, Chunhoo Yoo, Jeong-Eun Yoo, Hwa-Seung Cho, Chong-Kwan Kang, Sohyeon Kim, Mia Jang, Bo-Hyoung Shin, Yong-Cheol Ko, Seong-Gyu |
author_sort | Cheon, Chunhoo |
collection | PubMed |
description | BACKGROUND: Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. OBJECTIVE: The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. METHODS: A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. RESULTS: Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. CONCLUSIONS: Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov NCT02468141. |
format | Online Article Text |
id | pubmed-5758845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-57588452018-02-13 Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial Cheon, Chunhoo Yoo, Jeong-Eun Yoo, Hwa-Seung Cho, Chong-Kwan Kang, Sohyeon Kim, Mia Jang, Bo-Hyoung Shin, Yong-Cheol Ko, Seong-Gyu Evid Based Complement Alternat Med Research Article BACKGROUND: Anorexia occurs in about half of cancer patients and is associated with high mortality rate. However, safe and long-term use of anorexia treatment is still an unmet need. OBJECTIVE: The purpose of the present study was to examine the feasibility of Sipjeondaebo-tang (Juzen-taiho-to, Shi-Quan-Da-Bu-Tang) for cancer-related anorexia. METHODS: A total of 32 participants with cancer anorexia were randomized to either Sipjeondaebo-tang group or placebo group. Participants were given 3 g of Sipjeondaebo-tang or placebo 3 times a day for 4 weeks. The primary outcome was a change in the Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes included Visual Analogue Scale (VAS) of anorexia, FAACT scale, and laboratory tests. RESULTS: Anorexia and quality of life measured by FAACT and VAS were improved after 4 weeks of Sipjeondaebo-tang treatment. However, there was no significant difference between changes of Sipjeondaebo-tang group and placebo group. CONCLUSIONS: Sipjeondaebo-tang appears to have potential benefit for anorexia management in patients with cancer. Further large-scale studies are needed to ensure the efficacy. TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov NCT02468141. Hindawi 2017 2017-12-26 /pmc/articles/PMC5758845/ /pubmed/29441116 http://dx.doi.org/10.1155/2017/8780325 Text en Copyright © 2017 Chunhoo Cheon et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Cheon, Chunhoo Yoo, Jeong-Eun Yoo, Hwa-Seung Cho, Chong-Kwan Kang, Sohyeon Kim, Mia Jang, Bo-Hyoung Shin, Yong-Cheol Ko, Seong-Gyu Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title_full | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title_fullStr | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title_full_unstemmed | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title_short | Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial |
title_sort | efficacy and safety of sipjeondaebo-tang for anorexia in patients with cancer: a pilot, randomized, double-blind, placebo-controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758845/ https://www.ncbi.nlm.nih.gov/pubmed/29441116 http://dx.doi.org/10.1155/2017/8780325 |
work_keys_str_mv | AT cheonchunhoo efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT yoojeongeun efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT yoohwaseung efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT chochongkwan efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT kangsohyeon efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT kimmia efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT jangbohyoung efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT shinyongcheol efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial AT koseonggyu efficacyandsafetyofsipjeondaebotangforanorexiainpatientswithcancerapilotrandomizeddoubleblindplacebocontrolledtrial |